top of page

Digital Therapeutics Companies Lean into Decentralized Clinical Trials

While digital therapeutics (DTx) companies are extremely optimistic about the promise of software-based interventions to prevent and treat diseases, they are still navigating unchartered territories around the best practices for clinical research, including patient recruitment and retention, quality of data, high costs, and uncertainty around regulatory guidelines.

At the same time, clinical trial models are rapidly evolving, adding further complexities. But one thing DTx companies do agree on is that the decentralized clinical trial (DCT) model is key to overcoming their biggest hurdles and improving the entire clinical research process.

Read the full article, including a quote from our co-founder and Chief Medical Officer, Dr. Michael Aratow, here.


bottom of page